News
LXRX
2.271
-2.53%
-0.059
Lexicon Pharmaceuticals to present at H.C. Wainwright BioConnect Investor Conference
PUBT · 3d ago
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 4d ago
Lexicon Pharma Price Target Raised to $3.10/Share From $2.30 by Citigroup
Dow Jones · 4d ago
Lexicon Pharma Is Maintained at Buy by Citigroup
Dow Jones · 4d ago
Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $3.1
Benzinga · 4d ago
Lexicon price target raised to $3.10 from $2.30 at Citi
TipRanks · 4d ago
Weekly Report: what happened at LXRX last week (0504-0508)?
Weekly Report · 4d ago
Lexicon Pharmaceuticals: Buy Rating Reiterated as Value Catalysts Build; $6 Price Target Maintained
TipRanks · 05/08 10:55
Lexicon anticipates SONATA-HCM enrollment completion by mid-2026 while highlighting $100m Hercules debt facility
Seeking Alpha · 05/07 21:12
Lexicon reports Q1 EPS 0c, consensus (4c)
TipRanks · 05/07 19:12
Lexicon Pharmaceuticals Q1 net loss narrows
Reuters · 05/07 11:41
Lexicon Pharmaceuticals reports Q1 results
Seeking Alpha · 05/07 11:41
Lexicon Pharmaceuticals Q1 Sales $1.090M Miss $9.380M Estimate
Benzinga · 05/07 11:31
BRIEF-Lexicon Pharmaceuticals Q1 EPS USD -0.01
Reuters · 05/07 11:30
LEXICON PHARMACEUTICALS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATES
Reuters · 05/07 11:30
*Lexicon Pharma 1Q Loss $1.04M >LXRX
Dow Jones · 05/07 11:30
*Lexicon Pharma 1Q EPS 0c >LXRX
Dow Jones · 05/07 11:30
*Lexicon Pharma 1Q Rev $21.1M >LXRX
Dow Jones · 05/07 11:30
Press Release: Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
Dow Jones · 05/07 11:30
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
Barchart · 05/07 06:30
More
Webull provides a variety of real-time LXRX stock news. You can receive the latest news about Lexicon Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About LXRX
Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders.